tbuckley/cabot-search huggingface dataset:
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
Authors: Luke Maese, Rachel E. Rau, Elizabeth A. Raetz, Tong Lin, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, L. Mi Rim Choi, Mignon L. Loh, Peter C. Adamson
Journal: Journal of Clinical Oncology (2020)

TPS7568 Background: L-asparaginase is an important component of ALL therapy and the inability to receive asparaginase secondary to hypersensitivity has been associated with poor patient (pt) outcomes. Alternative options for pts after hypersensitivity reactions are needed. JZP-458 is a recombinant Erwinia asparaginase produced using a novel Pseudomonas fluorescens expression platform that yields an enzyme with no immunologic cross-reactivity to E. coli–derived asparaginases. In a phase 1 study, JZP-458 was well tolerated and maintained adequate (≥0.1 IU/mL) serum asparaginase activity (SAA), a surrogate marker for asparagine depletion, for up to 72 hrs in healthy adults. Methods: This is a pivotal, open-label, multicenter, dose confirmation, and pharmacokinetic (PK) study (NCT04145531) of JZP-458 in pts with ALL/LBL who develop hypersensitivity reactions to a long-acting E. coli–derived asparaginase and have ≥1 course of asparaginase remaining in their treatment plan (Table); 6 doses of JZP-458 will be substituted for each remaining course. Treatment duration will depend on the number of asparaginase courses remaining in the treatment plan. The study has 2 sequential parts: Part A will determine the dose of intramuscular (IM) JZP-458 and confirm safety/efficacy; Part B will explore the dose/schedule of intravenous (IV) JZP-458. Blood samples will be collected to determine SAA levels and pts will be monitored for adverse events. Immunogenicity of JZP-458 will be assessed. Primary objectives are to determine (1) the efficacy of IM JZP-458 measured by the last 72-hr nadir SAA (NSAA) level (≥0.1 IU/mL) during the first treatment course, and (2) the safety/tolerability of IM JZP-458. Secondary objectives are to determine the efficacy (measured by the last 48-hr NSAA level [≥0.1 IU/mL] and the last 48- and 72-hr NSAA levels [≥0.4 IU/mL]), PK, and immunogenicity of IM JZP-458. Exploratory objectives include efficacy, safety, PK, and immunogenicity of IV JZP-458. The trial is active and enrolling. Clinical trial information: NCT04145531 . [Table: see text]
经右胸腋下小切口行儿童先天性心脏畸形矫治术143例分析
Authors: 康敢军, 程邦昌, 毛志福, 黄杰, 林道明
Journal: BMJ (2008)

近年来,随着心脏外科技术的成熟,手术安全性的提高,采用胸部不同部位小切口完成心内直视手术日渐增多[1-2].我院自1996年3月至2004年9月,采用右胸腋下小切口完成儿童先天性心脏病心内畸形矫治手术143例,现总结如下。
大疱性表皮松解症伴食管上段狭窄一例
Authors: 王盛根, 王寿九, 涂金兰, 谷丽娟, 曾庆菊, 吴玉纯
Journal: BMJ (2006)

患者男,17岁,学生.因吞咽困难16年余,加重1年半于2005年11月8日就诊.患者自1岁左右开始进固体状饭食,家长发现其吞咽慢,进食时间相当于同龄人的2倍.长大后自觉进食时胸骨上窝后有梗阻感,以进固体食物时明显。
Causes of death in patients with ST-segment elevation myocardial infarction following primary percutaneous coronary intervention
Authors: Jianfu Wang, Qinping Li, Yanjin Wei
Journal: BMJ (2018)

Objective
To analyze the causes of death in patients with ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI).


Methods
The clinical data of 1 213 patients [845 males and 368 females, mean age: (60.83±12.31) years] with STEMI who underwent direct PCI in Linyi People's Hospital from January 2010 to May 2014 and followed-up for 3-7 years were retrospectively analyzed. The causes of death and predictors were analyzed.


Results
Among 1 135 patients, 129 died during the follow-up. Thirty nine patients died in the first 2 weeks and 97.4% (38/39)due to cardiovascular causes; 29 died between 2 weeks and 1 year and 62.1% (18/29)due to cardiovascular causes; 61 died after 1 year and 40.9% (25/61)from cardiovascular causes, 19.7% (12/61) from cancer, 14.8% (9/61)from stroke. Multivariate Cox regression analysis showed that age ≥70 years, increase of serum creatinine, LVEF≤40%, symptom-to-balloon time>360 min, cardiac shock, triple vessel lesion, TIMI blood flow less than grade 3 were independent predictors of all death.


Conclusion
Cardiovascular conditions are the main cause of death in the first year and non-cardiovascular conditions are the main cause of death 1 year after primary PCI in patients with STEMI. It is suggested that long-term surviving patients should also pay close attention to non-cardiac risk factors.


Key words: 
Myocardial infarction; Percutaneous coronary intervention; Death
A single-center analysis of adjuvant sequential versus ‘sandwich’ chemoradiotherapy for patients with stage III endometrial cancer.
Authors: Janice Shen, James Newman, Jennifer Hernandez, Beatrice Bloom, Jean Kyung Lee, Veena S. John
Journal: Journal of Clinical Oncology (2020)

e18101 Background: To determine if the sequencing of chemotherapy with external beam radiotherapy (EBRT) in the adjuvant setting for FIGO stage III endometrial cancer impacts 2-year progression free survival (PFS). Methods: As part of our Gynecologic Oncology Multidisciplinary Group's initiative to establish an institutional guideline for the adjuvant treatment of Stage III endometrial cancer, we reviewed 144 cases identified by our cancer registry and departmental database. Treatment regimens were divided into three categories: sequential therapy with six cycles of carboplatin/taxane followed by EBRT, concurrent cisplatin for two cycles with EBRT followed by four cycles of carboplatin/taxane, or ‘sandwich’ therapy with three cycles of carboplatin/taxane followed by EBRT followed by three cycles of carboplatin/taxane. The published results of the phase III GOG-258 study called into question the efficacy of concurrent chemoradiation. Therefore, we only compared sequential versus ‘sandwich’ therapy using a Chi-Square analysis. We conducted a retrospective chart review to assess if patients were able to complete the prescribed six cycles and EBRT, and then measured their PFS at two years. We hypothesized that there would be no difference in PFS between the two groups. Results: There were no significant differences in clinical or pathologic factors between patients treated with either regimen. Ninety-four patients (65%) had stage IIIC disease. The majority of patients received six cycles of paclitaxel with carboplatin. Median EBRT dose was 45 Gy. There was no statistically significant difference in the estimated 2-year PFS between the sequential and ‘sandwich’ groups, which were 82% and 82.5%, respectively (p = 0.84). Conclusions: Adjuvant chemoradiation for FIGO stage III endometrial cancer given sequentially or in a ‘sandwich’ fashion appears to offer equally excellent early clinical patient outcomes.
乙型肝炎病毒感染的临床诊断及处理
Authors: 陈志海
Journal: BMJ (2008)

陈志海:我将采用一种新的方法,分析几个典型的乙型肝炎(乙肝)案例,然后再分析案例背后的理论基础.如果大家对这些案例真正地掌握了,那就基本上掌握了乙肝的各种类型,包括什么是携带者?什么是慢性乙肝?什么是急性乙肝?什么是乙肝后肝硬化?遇到这些病例该怎么办.
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Authors: Salvatore Siena, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez, Javier Rodriguez, Fortunato Ciardiello, Kapil Saxena, Eriko Yamamoto, Emarjola Bako, Yasuyuki Okuda, Javad Shahidi, Axel Grothey, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2020)

4000 Background: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. Early studies have shown promising activity in advanced HER2-expressing tumors. DESTINY-CRC01 (DS8201-A-J203; NCT03384940) is a phase 2, open-label, multicenter study of T-DXd in pts with HER2-expressing mCRC. Methods: Pts with centrally confirmed HER2-expressing, RAS–wild type mCRC that progressed on ≥ 2 prior regimens received T-DXd 6.4 mg/kg every 3 weeks (q3w) in 3 cohorts (A: HER2 IHC 3+ or IHC 2+/ISH+; B: IHC 2+/ISH−; C: IHC 1+). The primary endpoint was confirmed objective response rate (ORR) by independent central review in cohort A; secondary endpoints included, disease control rate (DCR; CR + PR + SD), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and ORR in cohorts B and C. Results: At data cutoff (Aug 9, 2019), 78 pts (A, 53; B, 7; C, 18) had received T-DXd. Median age was 58.5 y (range, 27-79 y), 52.6% of pts were male, and 89.7% had left colon or rectum cancer; median number of prior regimens was 4 (range, 2-11); all pts had prior irinotecan. Median treatment duration was 3.5 mo (95% CI, 2.1-4.3 mo; cohort A, 4.8 mo [95% CI, 3.9-5.8 mo]); 38.5% of pts remained on T-DXd treatment. The confirmed ORR was 45.3% (24/53 pts; 95% CI, 31.6%-59.6%) in cohort A, including 1 CR and 23 PRs; median DOR was not reached (95% CI, 4.2 mo-NE). The ORR in pts with prior anti-HER2 treatment was 43.8% (7/16 pts; 95% CI, 19.8%-70.1%). The DCR was 83.0% (44/53 pts; 95% CI, 70.2%-91.9%); median PFS was 6.9 mo (95% CI, 4.1 mo-NE); median OS was not reached. No responses were observed in cohorts B or C. Grade ≥ 3 treatment-emergent adverse events (TEAEs) occurred in 61.5% of pts (48/78); the most common (≥10%) were decreased neutrophil count (21.8%) and anemia (14.1%). Seven pts (9.0%) had TEAEs leading to drug discontinuation. Five pts (6.4%) had interstitial lung disease (ILD) adjudicated by an independent committee as related to T-DXd (2 grade 2; 1 grade 3; 2 grade 5 [the only drug-related deaths]). Conclusions: Overall, T-DXd 6.4 mg/kg q3w demonstrated remarkable activity in pts with HER2-expressing mCRC refractory to standard therapies, with a safety profile consistent with previous results. ILD is an important risk and requires careful recognition and intervention. Clinical trial information: NCT03384940 .
Survey on job satisfaction of general practitioners who completed residency training in Zhongshan Hospital
Authors: Jian Wang, Zhigang Pan, Qi Zhao
Journal: BMJ (2016)

Objective
To survey job satisfaction of general practitioners (GP) who completed residency training program in Zhongshan Hospital, Fudan University.


Methods
One hundred and fifty two GPs who completed residency training program in Zhongshan Hospital and were currently working in community health service centers in Shanghai participated in the study. Job satisfaction was surveyed with Minnesota job satisfaction questionnaire and self-designed job satisfaction questionnaire.


Results
Total 152 questionnaires were distributed and 152 effective questionnaires were recovered with a response rate of 100%. The overall score of job satisfaction was 60.26±16.47, the mean score of internal satisfaction was 60.13±15.13 and the mean score of external satisfaction was 60.08±15.07. Linear regression analysis showed that there were no significant differences in overall, internal and external job satisfaction scores among participants with different gender, age, education level, job title, work duration and work location. Besides pay, participants valued the opportunities of upgrading working capability, job achievement, harmonious interpersonal relationships and good working environment. 21.1%(32/152)of the participants were satisfied with their job and 26.3%(40/152)were not satisfied or even wanted to leave their job. The main reason for dissatisfaction was low income(100.0%); other reasons included lacking opportunity of upgrading clinical skills(72.5%, 29/40)and poor working conditions(35.0%, 14/40). Only 11.8%(18/152)of the participants thought that their work was recognized by their chief and peers. 52.6%(80/152)thought that their abilities had not been fully developed and 7.2%(11/152)did not have any chance to display their abilities. 61.8%(94/152) thought that they were over burdened. Only 9.3%(14/152)thought that medical work is respectable by the society.


Conclusion
The job satisfaction of GPs who completed residency training in Zhongshan Hospital seems to be not high. Raising the salaries, providing more supports, giving individualized training and adopting mechanism of job stimulation for them are the major ways to improve their job satisfaction.


Key words: 
Job satisfaction; Questionnaires; General practitioners
Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
Authors: Xuexiao Jin, Qin Xu, Chengfei Pu, Kaixiang Zhu, Cheng Lu, Yu Jiang, Lei Xiao, Yongmei Han, Linrong Lu
Journal: Cellular and Molecular Immunology (2020)
The application of hemoglobin and transferrin immunoassay in detection of digestive tract bleeding
Authors: Da-guang Wang, Xiao-feng Yang, Jin-hua Zhang
Journal: BMJ (2009)

Fecal samples were collected from 81 patients with digestive tract bleeding (including 32 cases of upper digestive tract bleeding, 6 gastric cancer, 34 lower digestive tract ulcer and 9 colorectal cancer) and 40 healthy subjects. Fecal occult blood was detected with hemoglobin and/or transferrin monoclonal immunoassay. The positive rate with hemoglobin immunoassay for upper digestive tract bleeding, gastric cancer, lower digestive tract ulcer and colorectal cancer was 46.9%, 66.7%, 32.3% and 77.8% respectively;the positive rate with transferrin imrnunoassay was 71.9%, 83.3%, 47.1% and 88.9% respectively. When two methods were combined, the positive rate increased to 87.5%, 100%, 55.9% and 100% respectively showing a higher sensitivity.

Key words: 
Transferrin; Hemoglobins
外科病房护理晨查房模式的转变与体会
Authors: 李健, 周玉洁
Journal: BMJ (2006)

晨查房是早晨各班次护士与夜班护士进行交接,了解患者病情变化、将患者的信息有效地传递给医生,并不断提高观察患者能力的重要环节.我病房以往的晨查房过程为夜班护士巡视病房准备交班,护士长和主管护士提前到岗进入病房了解患者情况,8时准时与医生一起在办公室交接班,交班后再由护士长带领全体护士对病房全体患者进行总查房.此种形式查房虽能够全面地掌握患者情况,但查房次数较多,不仅影响患者休息,而且反映出各班、各层人员的沟通不够,浪费了晨间宝贵的时间和人力.我病房从2006年1月至6月尝试改变晨查房的模式,由护士长带领主管护士、夜班和辅助护士一同对病房内重点患者查房,对患者的病情进行个性化评估,减少查房次数、缩短查房时间。
Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
Authors: Andrew Dagens, Louise Sigfrid, Erhui Cai, Sam Lipworth, Vincent Cheng, Eli Harris, Peter Bannister, Ishmeala Rigby, Peter Horby
Journal: BMJ (2020)

To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic.Rapid review.Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network.Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included.Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS.2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people.Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations.PROSPERO CRD42020167361.
Unification at the cost of realism and precision
Authors: Rachael L. Brown, Carl Brusse, Bryce Huebner, Ross Pain
Journal: Behavioral and Brain Sciences (2020)

Abstract Veissière et al. must sacrifice explanatory realism and precision in order to develop a unified formal model. Drawing on examples from cognitive archeology, we argue that this makes it difficult for them to derive the kinds of testable predictions that would allow them to resolve debates over the nature of human social cognition and cultural acquisition.
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
Authors: David S. Hong, Brian A. Van Tine, Anthony J. Olszanski, Melissa Lynne Johnson, David A. Liebner, Trupti Trivedi, Quan Lin, Erica Elefant, Rebecca Dryer-Minnerly, Jean-Marc Navenot, Dennis Williams, Indu R. Ramachandran, Paula M. Fracasso, Elliot Norry, Marcus O. Butler
Journal: Journal of Clinical Oncology (2020)

102 Background: MAGE-A4 is a cancer/testis antigen with expression in many solid tumors promoting cell growth by preventing cell cycle arrest and apoptosis. This study (NCT03132922) evaluated safety and efficacy of SPEAR T-cells directed against the MAGE-A4 peptide expressed in 9 tumor types. Methods: This Phase I dose-escalation, expansion trial evaluated patients (pt) who were HLA-A*02 positive with advanced cancers that expressed the MAGE-A4 protein. Autologous T-cells from eligible patients were isolated, transduced with a lentiviral vector containing the MAGE-A4 c1032 TCR, and expanded. Prior to ADP-A2M4 infusion, pts received a lymphodepletion regimen of cyclophosphamide and fludarabine. Cohorts 1, 2, 3, and expansion were to receive transduced cell doses of up to: 0.12 × 10 9 , 1.2 × 10 9 , 6 × 10 9 , and 10 x 10 9 , respectively. Results: As of 23 October 2019, 9 pts were treated in dose escalation with no DLTs; 25 pts were treated in expansion. Median age was 56.5 yr (range: 31-78). All pts received prior chemotherapy. Most common ( &gt; 30%) AEs ≥Grade 3 were lymphopenia, leukopenia, neutropenia, anemia, thrombocytopenia, and febrile neutropenia. Two pts had trial-related deaths (aplastic anemia and CVA) leading to modification of the lymphodepletion regimen and eligibility criteria. In Cohort 3/expansion (28 pts), Best Overall Response was PR (7), SD (11), PD (5), non-evaluable (5). All PRs, at the time of data cut-off, were in patients with synovial sarcoma. Transduced T-cells were detectable in all patients. Tumor infiltration of SPEAR T-cells was detectable in several cohort 3/expansion pts. Conclusions: The Phase I single agent ADP-A2M4 trial will complete enrollment shortly and updated data will be presented. ADP-A2M4 shows promising efficacy and a manageable safety profile at a dose range of 1.2 – 10 × 10 9 . Clinical activity in various tumors has led to a separate on-going low dose radiation sub-study of this trial, a Phase II trial in sarcoma (SPEARHEAD-1, NCT04044768), and a Phase I trial (SURPASS, NCT04044859) with ADP-A2M4CD8, a next-generation SPEAR T-cell targeting MAGE-A4. Clinical trial information: NCT03132922.
Comparison of three different surgical modalities in treatment of varicose veins
Authors: Wenli Wang, Zhilei Xie
Journal: BMJ (2015)

Total 215 patients with simple varicosis of great saphenous vein underweni surgical treatment in our hospital from February 2007 to January 2012, including 75 cases receiving traditional high ligation segmentation stripping operation (group A), 69 cases receiving endovenous laser light therapy (group B), and 71 receiving minimally invasive translucent atherectomy (group C). The efficacy and postoperative complications were compared among 3 groups. The operation time, intraoperational bleeding and length of hospitalization in groups B and C were significantly less than those in group A (P<0.05). The hospitalization cost of groups A and B was significantly lower than that of group C (P<0.05). The incidence of subcutaneous induration in groups A and B was significantly higher than that of group C (P<0.05). The incidence of subcutaneous congestion in group A was significantly higher than that in groups B and C (P<0.05). The recurrence rate during 2-years of follow-up in groups A and B was higher than that in group C (χ2=8.592, 5.672, P=0.003, 0.016). Three surgical modalities in treatment of great saphenous varicose veins have advantage and disadvantages, the appropriate methods should be chosen based on the characteristics of procedures and the condition and intention of patients.

Key words: 
Varicose veins;  Vascular surgical procedures
Cognitive impairment, dementia and diabetes
Authors: Shuolin Wu
Journal: BMJ (2018)

认知功能障碍(认知功能损伤及痴呆)及糖尿病是严重威胁人类生存质量的慢性疾病，二者之间有着共同的病理生理机制和危险因素。阿尔茨海默病甚至被称为3型糖尿病，其发病机制与高血糖、高胰岛素血症、脂代谢紊乱等引起脑胰岛素代谢异常、血管调节功能障碍及乙酰胆碱、淀粉样物质和Tau蛋白、氧化应激及糖基化终末产物等有关。认知功能受损进一步加重糖尿病的损害。糖尿病与认知功能损伤及痴呆相互加重，形成双向的恶性循环。在二者的治疗中应该充分考虑到上述特点，尽早给予生物、心理、社会多维度的全面管理。
Detection of pancreatic cancer using a novel blood-based DNA methylation signature.
Authors: Nishant Munugala, Hytham Hammad, Lukas Vrba, Marc Oshiro, Betsy Wertheim, Denise Roe, Hemanth Gavini, Leah Latura, Daniel Pennington, Shelby Dalgai, Hani M. Babiker, Emad Elquza, Aaron James Scott, Mark Nelson, Bernard W. Futscher, Rachna T. Shroff
Journal: Journal of Clinical Oncology (2020)

e15546 Background: Pancreatic cancer (PC) is a high mortality malignancy typically found when curative surgery is not an option. Liquid biopsies are a minimally invasive option that may allow earlier detection of PC. Using a bioinformatic analysis of TCGA and GEO we identified a novel set of blood-based biomarkers to detect PC with high sensitivity and specificity (AUROC = 0.999) (Vrba et al, Epigenetics 2019). Here we tested the ability of this DNA methylation signature (MS) to distinguish metastatic PC from pancreatic cysts (Cy) and healthy controls (HC) through quantitative DNA methylation analysis of cell free DNA (cfDNA). Methods: A 10 gene DNA methylation marker set that identifies PC was used to evaluate the cfDNA component of the plasma of PC patients, Cy patients and HC. The ROC analysis and AUC calculations were performed using the R library pROC (Robin et al, BMC Bioinformatics 2011). Plasma samples were collected in cfDNA collection tubes from patients with benign Cy, PC, and HC. Clinical information was collected including age, gender, smoking history, CA 19-9 level, cyst size, presence of liver metastases, and survival status. After processing and cfDNA extraction, qRT-PCR methylation analysis was performed on these prospectively collected samples. The difference in median DNA MS per marker of the full 10-gene marker set between the above groups was analyzed by Wilcoxon rank sum test and ROC analysis. A Cox proportional hazard regression model was used to test the association between MS and survival. Results: A total of 66 samples were collected (PC = 10, Cy = 12, HC = 44). Clinical information was collected on all patients included in the analysis. Using liquid biopsies for cfDNA analysis and a novel set of DNA methylation biomarkers, MS was substantially stronger in PC (median, 13.2) patients than Cy (median, 3.5) patients (p = 0.0001). Importantly, while there was no clear association between MS and age, gender, smoking status, CA 19-9 levels, or presence of liver metastases, higher methylation levels were non-significantly associated with worse overall survival in PC patients (HR, 1.29; 95% CI, 0.97–1.72; p = 0.082). Conclusions: While this is a small sample size, early findings suggest that a DNA MS may reliably distinguish PC from benign Cy. The strength of signal may be a prognostic marker that could play a role in determining treatment approaches. Given its utility in predicting PC, future directions include testing this tool as a blood-based early detection mechanism as well as a predictor for recurrence or response to PC treatment.